NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Fabtech Technologies CFO Kalpesh Chauhan Resigns Effective November 12, 2026
Fabtech Technologies Limited announced that Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) Mr. Kalpesh Chauhan has tendered his resignation effective from the close of business hours on November 12, 2026. The resignation is attributed to personal and professional reasons, with no immediate successor announced in the filing. Fabtech, which operates with a market cap of Rs 698 Cr and TTM revenue of Rs 364 Cr, faces volatile project-driven earnings, making stable financial leadership critical. Investors will need to track the appointment of a new CFO to manage the company's working capital cycles and turnkey project execution.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Kalpesh Chauhan has resigned as CFO and KMP of Fabtech Technologies, stepping down on November 12, 2026.
ஏன் இது முக்கியம்A sudden departure of the CFO introduces leadership transition risk, particularly for a project engineering firm with lumpy revenue recognition and working capital dependencies.
Effective cessation date: நவம்பர் 12, 2026Company Market Cap: Rs 698 கோடிTTM வருவாய்: Rs 364 கோடி
📅 குறுகிய காலம்May cause minor sentiment weakness given the departure of a key managerial person without an immediate replacement in place.
📈 நீண்ட காலம்Limited, provided the company executes a smooth handover and appoints a qualified finance head to oversee project cash flows.
⚠ அபாய எச்சரிக்கைகள்
Key person departure with no successor announced yet
Execution and working capital oversight risks during leadership transition
👀 கவனிக்க வேண்டியவை
Monitor upcoming board meeting outcomes for the announcement of an interim or permanent CFO successor, as well as commentary on working capital management.
Fabtech Reports Q2 Revenue at ₹92.09 Cr (+22.8% QoQ); Order Book Exceeds ₹900 Cr
Fabtech Technologies released its Q2 FY27 earnings call transcript, highlighting sequential revenue growth of 22.8% to ₹92.09 crore and an EBITDA jump of 110% QoQ to ₹15.57 crore. Adjusted PAT grew to ₹8.45 crore compared to ₹4.21 crore in Q1 FY27, while reported PAT included an exceptional item of ₹6.59 crore. The order book stood at over ₹900 crore (equivalent to ~2.5x TTM revenue of ₹364 crore), with an additional prospective pipeline of ₹800-850 crore. Working capital challenges remain in focus, with net trade receivables at ₹226 crore (₹81 crore overdue) and negative operating cash flows of ₹41 crore in H1.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech disclosed its detailed Q2 & H1 FY27 conference call transcript discussing operating trends, margins, and balance sheet status.
ஏன் இது முக்கியம்The company demonstrated sequential recovery from Q1 execution lows, supported by a healthy order book of over ₹900 crore, although working capital and negative operating cash flows pose near-term hurdles.
Q2 FY27 Revenue: INR 92.09 croreQ2 FY27 EBITDA: INR 15.57 croreOrder Book: over INR 900 croreOrder Book vs TTM Revenue: ~247%Net Receivables: almost INR 226 crores
📅 குறுகிய காலம்Earnings operational recovery in Q2 provides sequential relief, but cash collection and working capital stretch will keep sentiment measured in the near term.
📈 நீண்ட காலம்The company is well positioned in emerging pharma infrastructure with an order book >₹900 crore, but margin preservation under fixed-price contracts and cash flow turnaround are crucial for structural re-rating.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow of ~₹41 crore in H1 FY27
High overdue receivables of ₹81 crore out of ₹226 crore net receivables
Geopolitical and freight disruptions in GCC markets
👀 கவனிக்க வேண்டியவை
Track cash flow conversion and the collection of the ₹50 crore overdue receivables in upcoming quarters, along with project execution pace in Saudi Arabia and Africa.
Fabtech Q2 FY27 EBITDA jumps 110% QoQ to ₹15.57 Cr; order book stands at ₹900+ Cr
Fabtech Technologies released its Q2 & H1 FY27 investor presentation, reporting Q2 revenue from operations of ₹92.09 Cr, up 22.8% QoQ, and EBITDA of ₹15.57 Cr, up 110% QoQ. Reported PAT stood at ₹15.02 Cr, supported by an exceptional gain of ₹6.59 Cr, bringing Adjusted PAT to ₹8.43 Cr (up 99.1% QoQ). The unexecuted order book remains robust at over ₹900 Cr (~2.47x TTM revenue of ₹364 Cr), with prospective pipeline bids of ₹800-850 Cr across Africa and Saudi Arabia. Management reiterated its full-year FY27 adjusted PAT margin target of 8–9%.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the Q2 & H1 FY27 comprehensive investor presentation following unaudited financial results.
ஏன் இது முக்கியம்Demonstrates sequential operational recovery with EBITDA doubling QoQ and confirms strong revenue visibility backed by a ₹900+ Cr order book.
📅 குறுகிய காலம்Sequential recovery in margins and robust commentary on Africa and GCC executions should support investor sentiment after previous margin weakness.
📈 நீண்ட காலம்Long-term scaling depends on timely execution of the turnkey order book across GCC/Africa, managing freight/geopolitical costs, and expanding into advanced life-sciences and cell/gene therapy facilities.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical uncertainty and freight cost volatility in Middle East/GCC markets
High working capital requirements with trade receivables standing at ₹226.1 Cr in H1 FY27
Lumpy project milestone-based revenue recognition
👀 கவனிக்க வேண்டியவை
Track the execution run-rate in H2 FY27 to verify if project milestones convert the ₹900+ Cr order book into targeted 8-9% full-year adjusted PAT margins.
Fabtech Q2 FY27 Consolidated PAT at ₹15.02 Cr, Order Book Reaches ~₹900 Cr
Fabtech Technologies reported Q2 FY27 consolidated revenue of ₹92.09 Cr (920.9 million), down 24.2% YoY from ₹121.48 Cr in Q2 FY26, but up 22.8% QoQ. Net profit for the quarter fell 46.6% YoY to ₹15.02 Cr (₹150.2 million) compared to ₹28.11 Cr in Q2 FY26. Profitability was impacted by elevated freight and logistics costs, war-risk surcharges, and non-recurring site security expenses in the Middle East. The company maintains an active order book of ~₹900 Cr (2.47x TTM revenue) with prospective bids worth ₹800-850 Cr under discussion.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech announced its Q2 & H1 FY27 results, showing sequential recovery from Q1 FY27 but lower year-on-year revenues and margins due to geopolitical freight disruptions.
ஏன் இது முக்கியம்The company's order book of ~₹900 Cr (approx. 247% of TTM revenue) ensures strong multi-quarter revenue visibility, but margin recovery hinges on delivering back-ended H2 milestones.
Q2 FY27 Revenue: ₹920.9 millionQ2 FY27 PAT: ₹150.2 millionCurrent Order Book: ~₹900 கோடிOrder Book vs TTM Revenue: ~247%Pipeline Under Discussion: ₹800-850 Cr
📅 குறுகிய காலம்Sequential margin improvement (from 5.6% to 16.3% PAT margin QoQ) is positive, though markets may remain watchful of ongoing freight volatility in Middle East project execution.
📈 நீண்ட காலம்Solid positioning in emerging market turnkey pharma infrastructure and a ₹900 Cr order book underpin medium-term growth if H2 execution conversion remains on schedule.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical unrest in GCC/Middle East impacting site operations and logistics
Customer milestone lumpiness inherent to turnkey project contracting
👀 கவனிக்க வேண்டியவை
Track the execution ramp-up in H2 FY27 and assess whether operating margins normalize as geopolitical freight surcharges and site-security idle costs abate.
Fabtech Q2 FY27 Results: Revenue at Rs 92.09 Cr; Alan Dias Appointed VP-HR as SMP
Fabtech Technologies reported standalone revenue from operations of Rs 92.09 Cr for the quarter ended September 30, 2026, up 22.8% sequentially from Rs 74.98 Cr in Q1 FY27, but down 24.2% YoY compared to Rs 121.48 Cr in Q2 FY26. Total income for the quarter stood at Rs 97.54 Cr. Additionally, foreign subsidiary Fabtech Technologies LLC (UAE) contributed revenue of Rs 40.00 Cr and PAT of Rs 4.53 Cr for the quarter. The Board also approved the appointment of Mr. Alan Dias, VP-HR, as a Senior Management Personnel.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech approved Q2 FY27 financial results and designated VP-HR Alan Dias as Senior Management Personnel.
ஏன் இது முக்கியம்The company shows sequential top-line improvement after a weaker Q1, although operations remain lower compared to the high-revenue quarters of late FY26.
Q2 FY27 Revenue from Operations (Standalone): Rs 92.09 கோடிQ1 FY27 Revenue from Operations (Standalone): Rs 74.98 கோடிQ2 FY26 Revenue from Operations (Standalone): Rs 121.48 கோடிUAE Subsidiary Revenue (Q2 FY27): Rs 40.00 கோடிUAE Subsidiary PAT (Q2 FY27): Rs 4.53 கோடி
📅 குறுகிய காலம்The market is likely to react neutrally to mildly positive on the sequential revenue rebound, though YoY contraction remains a drag.
📈 நீண்ட காலம்Performance will hinge on steady order execution in emerging markets and sustaining positive net margins given historical lumpiness.
👀 கவனிக்க வேண்டியவை
Track the execution and revenue conversion of the order book in upcoming quarters to evaluate if operating margins can sustain recovery from previous FY26 losses.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Fabtech executes settlement to sell remaining TSA stake to Thermax for ₹13.99 cr
Fabtech Technologies Limited has entered into a Settlement Agreement on September 29, 2026, to conclude the second and final tranche of its stake sale in TSA Process Equipments Private Limited to Thermax Limited. Under the revised terms, Fabtech will offload 2,23,440 equity shares for a total consideration of ₹13.986 crore (₹13,98,60,000). Thermax had previously acquired 51% of TSA in April 2024 under the original February 2024 Share Purchase Agreement. The transaction is expected to be completed by October 05, 2026, bringing an immediate cash inflow.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech revised consideration terms and signed a settlement agreement to finalize the sale of its remaining TSA Process Equipments shares to Thermax.
ஏன் இது முக்கியம்Provides an immediate liquidity infusion of ~₹13.99 crore to Fabtech from an entity that contributed zero revenue and net worth in the previous fiscal year.
Sale consideration: Rs. 13,98,60,000/-Shares to be sold: 2,23,440 equity sharesExpected completion date: அக்டோபர் 05, 2026Consideration vs Jun 2026 quarterly revenue: ~18.65%
📅 குறுகிய காலம்Positive sentiment driven by the non-dilutive liquidity inflow of ₹13.99 crore expected by October 05, 2026.
📈 நீண்ட காலம்Streamlines the company's portfolio by fully exiting TSA Process Equipments, allowing management to redeploy capital into core turnkey pharmaceutical engineering projects.
⚠ அபாய எச்சரிக்கைகள்
Execution of final settlement and cash receipt by October 05, 2026
👀 கவனிக்க வேண்டியவை
Track the completion confirmation expected by October 05, 2026, and monitor subsequent quarterly financials (Q3 FY27) to observe the accounting gain and cash inflow utilization.
Fabtech Technologies to Incorporate 100% Step-Down Subsidiary in Egypt
Fabtech Technologies Limited's Board has approved the incorporation of a wholly owned step-down subsidiary in Egypt via its UAE subsidiary, Fabtech Technologies LLC. The new entity will operate in Turnkey Pharma Projects, covering HVAC, MEP, cleanrooms, and machinery. The equity capital will be subscribed in cash at face value, giving the company 100% ownership. This move aligns with Fabtech's strategy to expand across the MENA region to capture emerging healthcare infrastructure demand.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech Technologies received board approval to incorporate a wholly owned step-down operating subsidiary in the Arab Republic of Egypt.
ஏன் இது முக்கியம்Establishes a direct local operating entity to pursue turnkey pharmaceutical infrastructure projects in the MENA region, supporting its stated geographic expansion strategy.
Shareholding percentage: 100%Cost of subscription: face value per shareInitial capital investment: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Neutral to mildly positive; minimal immediate financial impact as formal incorporation and regulatory clearances are pending.
📈 நீண்ட காலம்Supports strategic expansion into high-potential MENA pharma markets seeking local manufacturing self-reliance, potentially broadening the project bidding pipeline.
⚠ அபாய எச்சரிக்கைகள்
Pending approvals from Egyptian regulators and the UAE Embassy
Geopolitical and currency risks associated with Egyptian operations
👀 கவனிக்க வேண்டியவை
Track the completion of regulatory approvals in Egypt and UAE, and watch for any disclosures regarding initial capital commitment and project wins in the MENA region.
Fabtech Wins ₹21 Cr Turnkey Project Entering New CIS Country
Fabtech Technologies has secured an international turnkey design-and-build order worth ₹21 crore in a CIS country, marking its entry into this new regional market. The project entails developing critical cleanroom and utility infrastructure for an advanced medical-device manufacturing facility. Execution is scheduled for handover within approximately 12 months from civil front availability. Against Q1 FY27 revenue of ₹74.98 crore, this single order represents roughly 28% of quarterly revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech expanded its geographic footprint into a CIS market by bagging a ₹21 crore medical-device infrastructure project.
ஏன் இது முக்கியம்Demonstrates the exportability of its turnkey single-window engineering model to severe-climate geographies and adds ₹21 crore to revenue visibility across the coming year.
Order value: ₹21 கோடிExecution timeline: approximately 12 monthsOrder vs Q1 FY27 revenue: ~28%
📅 குறுகிய காலம்Positive sentiment from international order inflow, though quarterly earnings impact will be spread across the 12-month delivery cycle.
📈 நீண்ட காலம்Validates engineering capabilities for severe climate zones and supports management's strategic focus on expanding turnkey pharmaceutical and medical infrastructure into emerging markets.
⚠ அபாய எச்சரிக்கைகள்
Severe climatic and operating conditions could cause execution delays or cost overruns
Customer-sourced process equipment creates dependency on external timelines before handover
Working capital stretch inherent in international fixed-price turnkey contracts
👀 கவனிக்க வேண்டியவை
Track the project's execution milestones and revenue recognition over the next 12 months, along with working capital impact given typical turnkey project cycles.
Step-Down Arm Completes 14,000 Sqm Facility for Himalaya Wellness in UAE in Under 1 Year
Fabtech Technologies announced that its UAE-based step-down subsidiary, FTS Cleanrooms Systems LLC, has completed a 14,000 sqm turnkey facility for Himalaya Wellness Company in Dubai Internet City. The project, which supports both pharmaceutical and cosmetic manufacturing operations, was delivered in less than one year via an integrated design-to-validation model. While the company did not disclose the financial contract value of this completed project, it showcases execution capabilities in the GCC region where Fabtech has targeted growth. In Q1 FY27 (Jun 2026), Fabtech reported revenue of ₹74.98 cr and PAT of ₹4.21 cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech's step-down subsidiary completed and handed over a 14,000 sqm turnkey facility to Himalaya Wellness in Dubai.
ஏன் இது முக்கியம்Demonstrates rapid execution (<1 year) for a marquee client in the GCC, supporting Fabtech's strategic expansion into high-growth international healthcare engineering markets.
Facility area: 14,000 sqmExecution timeframe: less than one yearProject contract value: வெளியிடப்படவில்லைQ1 FY27 Revenue: ₹74.98 கோடி
📅 குறுகிய காலம்Positive for sentiment regarding Fabtech's project execution track record, though financial impact remains unspecified as contract size was not disclosed.
📈 நீண்ட காலம்Validates Fabtech's integrated single-window delivery model in the MENA healthcare and personal care infrastructure space.
⚠ அபாய எச்சரிக்கைகள்
Commercial project value not disclosed
Lumpy project revenue cycles inherent to turnkey EPC engineering
👀 கவனிக்க வேண்டியவை
Track whether timely execution on landmark regional contracts converts into larger turnkey order wins in the MENA and GCC regions, as well as revenue conversion in upcoming quarterly results.
Fabtech Technologies Limited announced that its wholly owned UAE subsidiary, FTS Cleanrooms Systems LLC, has secured a turnkey project valued at AED 9.92 million (approximately ₹24.6 crore) from Aroma King, a UAE-based flavour manufacturer. The fast-track project is scheduled for completion within six months, representing ~32.8% of the company's Q1 FY27 revenue (₹74.98 crore). Scope includes delivery of modular controlled environments, cold rooms, specialised flooring, HVAC systems, and electrical works. This win marks the company's expansion beyond life sciences into high-specification food and flavour manufacturing infrastructure.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech's UAE subsidiary secured a new ₹24.6 crore fast-track turnkey infrastructure contract in the flavour manufacturing sector.
ஏன் இது முக்கியம்Adds immediate revenue visibility for the next two quarters and validates Fabtech's strategic diversification from pharmaceutical cleanrooms into broader food and flavour critical manufacturing infrastructure in the GCC.
Project Value (AED): AED 9.92 millionProject Value (INR): approximately ₹24.6 croreExecution Timeline: 6 மாதங்கள்Order vs Jun 2026 Revenue: ~32.8%
📅 குறுகிய காலம்Positive for sentiment given the sizeable order relative to quarterly revenue and clear 6-month execution runway.
📈 நீண்ட காலம்Demonstrates successful geographic and sector diversification across GCC markets beyond pure life sciences.
⚠ அபாய எச்சரிக்கைகள்
Fixed-price contract risks exposing margins to raw material/equipment price volatility
Strict 6-month fast-track delivery schedule
👀 கவனிக்க வேண்டியவை
Track execution progress and revenue recognition over the 6-month delivery timeline in upcoming quarterly results, along with margins from non-pharma project additions.
Q1 FY27 Turnaround: Fabtech reports Rs 4.21 Cr PAT and Rs 900 Cr+ Order Book
Fabtech Technologies achieved a significant turnaround in Q1 FY27, reporting a net profit of Rs 4.21 crore against a loss of Rs 6.13 crore in Q1 FY26. Revenue increased 10% YoY to Rs 74.98 crore, supported by a 130% surge in Saudi Arabian operations. The company maintains a massive order book exceeding Rs 900 crore, representing over 12x its current quarterly revenue. Management confirmed a 20-25% organic growth guidance for FY27, backed by a "hot lead" pipeline of Rs 3,800 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from a loss-making position to profitability with a 900 bps improvement in contribution margins.
ஏன் இது முக்கியம்The turnaround validates the company's strategy of localizing in high-margin markets like Saudi Arabia and Africa, reducing reliance on volatile regional segments.
📅 குறுகிய காலம்Positive sentiment is expected due to the return to profitability and strong revenue guidance for the full year.
📈 நீண்ட காலம்The shift toward a localized 'single window' model in emerging markets and expansion into broader infrastructure in Saudi Arabia could structurally re-rate the business.
👀 கவனிக்க வேண்டியவை
Monitor the execution of the Rs 900 crore order book and the completion of proposed acquisitions in Italy and Saudi Arabia by the end of FY27.
₹4.21 Cr PAT: Fabtech Swings to Profit in Q1 FY27 with 10.3% Revenue Growth
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a net profit of ₹4.21 Cr compared to a loss of ₹6.13 Cr in the same period last year. Revenue grew 10.3% YoY to ₹74.98 Cr, supported by a 910 bps expansion in contribution margins to 46.7%. The company maintains a massive open order book of over ₹900 Cr, which is approximately 12x its current quarterly revenue, providing high growth visibility. Management has guided for 20-25% organic growth for the full fiscal year FY27, with expectations of a stronger second half.
உச்சம் நம்பிக்கை
என்ன மாறியதுFabtech has transitioned from a loss-making quarter to profitability while achieving record-high contribution margins of 46.7%.
ஏன் இது முக்கியம்The turnaround and margin expansion demonstrate operating leverage and the successful deployment of IPO proceeds to reduce interest burdens. The large order book provides a multi-year revenue runway in the high-growth pharmaceutical engineering sector.
Revenue (Q1 FY27): ₹74.98 கோடிNet Profit (Q1 FY27): ₹4.21 கோடிOpen Order Book: ₹900+ CrOrder Book vs Q1 Revenue: 12.0xFY27 Growth Guidance: 20-25%Contribution Margin: 46.7%
📅 குறுகிய காலம்The stock is likely to react positively to the swing into profitability and the strong margin performance reported for the June quarter.
📈 நீண்ட காலம்The company is well-positioned to benefit from the 'medicinal independence' trend in emerging markets, supported by a massive project pipeline and an asset-light engineering model.
👀 கவனிக்க வேண்டியவை
Monitor the conversion of the ₹9,300+ Cr project pipeline into firm orders and the execution timeline of the existing ₹900 Cr order book. Investors should also track the working capital cycle, as the business is subject to lumpy project-based revenue recognition.
₹4.21 Cr PAT Turnaround: Fabtech Reports 10% Revenue Growth and ₹900 Cr Order Book in Q1 FY27
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a net profit of ₹4.21 Cr compared to a loss of ₹6.13 Cr in the same quarter last year. Revenue grew 10% YoY to ₹74.98 Cr, driven by a 130% surge in Saudi Arabian operations and strong contributions from new African markets like Morocco and Kenya (₹27.94 Cr). The company maintains a robust order book of over ₹900 Cr, providing high revenue visibility, and has guided for 20-25% organic growth for the full fiscal year. Profitability was further aided by a 36% reduction in finance costs following the strategic utilization of IPO proceeds.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a loss-making period to profitability with improved EBITDA margins (9.5%) and a strengthened balance sheet post-IPO.
ஏன் இது முக்கியம்The turnaround validates the company's 'single window' turnkey model in emerging markets and demonstrates its ability to scale internationally while reducing interest burdens.
📅 குறுகிய காலம்The stock is likely to react positively to the profit turnaround and the strong 20-25% growth guidance for FY27.
📈 நீண்ட காலம்Structural growth is supported by the global trend of 'medicinal independence' in emerging markets and a massive enquiry pipeline exceeding ₹9,300 Cr.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical delays in order finalization
Lumpy project-based revenue cycles
High dependency on third-party equipment for 70% of project value
👀 கவனிக்க வேண்டியவை
Watch for the conversion rate of the ₹3,800 Cr 'hot leads' into firm orders and the execution timeline of the African projects which now represent a major portion of revenue.
Fabtech Q1 FY27: Net Profit of ₹4.21 Cr; ₹0.60 Dividend Record Date Set for Aug 17
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a consolidated net profit of ₹4.21 cr compared to a loss of ₹6.13 cr in the same quarter last year. Revenue from operations grew 10.2% YoY to ₹74.98 cr. The company has fixed August 17, 2026, as the record date for a final dividend of ₹0.60 per share (6% of face value). Additionally, the board approved the re-appointment of Naushad Alimohmed Panjwani as Chairperson for a second five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from a quarterly loss to profitability and finalized the timeline for its FY26 dividend payment.
ஏன் இது முக்கியம்The turnaround indicates improved operational efficiency and project execution; the dividend and management continuity signal stability to the market.
Q1 FY27 Revenue: ₹74.98 கோடிQ1 FY27 Net Profit: ₹4.21 கோடிDividend per share: ₹0.60ரெக்கார்ட் தேதி: ஆகஸ்ட் 17, 2026Order Book (July 2025): ₹904.42 கோடி
📅 குறுகிய காலம்The stock may see positive momentum due to the profit turnaround and the upcoming dividend record date.
📈 நீண்ட காலம்Long-term value depends on the company's ability to scale its 'single window' turnkey model and maintain margins despite fixed-price contracts.
⚠ அபாய எச்சரிக்கைகள்
Lumpy project cycles causing revenue volatility
High dependency on third-party equipment for 70% of project value
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹904.42 cr order book to ensure the current profitability turnaround is sustained across lumpy project cycles.
Fabtech Technologies reported a consolidated revenue of ₹74.98 crore for Q1 FY27, marking a 10.2% increase from ₹68.01 crore in the same period last year. The company declared a final dividend of ₹0.60 per share (6% of face value) for FY26, with the record date set for August 17, 2026. A significant portion of the performance was driven by its UAE subsidiary, which contributed ₹28.51 crore to the top line. Additionally, the board approved the re-appointment of Mr. Naushad Panjwani as Chairperson for a second five-year term, ensuring leadership continuity.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported its first-quarter results for FY27, formalized its dividend payout timeline, and secured leadership for the next five years.
ஏன் இது முக்கியம்The results confirm steady growth in the turnkey pharmaceutical plant segment, particularly in international markets like the UAE, while maintaining shareholder returns through dividends.
Revenue (Q1 FY27): ₹74.98 கோடிRevenue Growth (YoY): 10.25%Dividend per share: ₹0.60UAE Subsidiary Revenue: ₹28.51 கோடிரெக்கார்ட் தேதி: ஆகஸ்ட் 17, 2026
📅 குறுகிய காலம்The stock may see neutral to positive movement as investors react to the revenue growth and the upcoming dividend record date in August.
📈 நீண்ட காலம்The re-appointment of the Chairperson and the focus on international subsidiaries suggest a stable long-term strategy to capture the 'medicinal independence' trend in emerging markets.
⚠ அபாய எச்சரிக்கைகள்
Lumpy project cycles causing quarterly volatility
High dependency on third-party equipment delivery (70% of project value)
👀 கவனிக்க வேண்டியவை
Investors should monitor the conversion of the ₹904.42 crore order book into revenue to see if the company can reach its 20% growth target, given the current 10.2% YoY quarterly growth.
Fabtech Technologies to Invest ₹26.49 Crore in Wholly-Owned Subsidiaries for Global Expansion
Fabtech Technologies has approved a significant capital infusion of up to ₹24 crore into its UAE-based subsidiary, Fabtech Technologies LLC, to strengthen its international EPC market presence. Additionally, the company will invest ₹2.49 crore in its Indian subsidiary, FT Institutions Private Limited, which has shown rapid growth with turnover increasing from ₹49.18 lakhs in FY24 to ₹1,261.56 lakhs in FY26. The board also noted the retirement of Independent Director Shyam Nagorao Khante and subsequently reconstituted its key committees. These moves indicate a focused strategy on scaling operations in the pharmaceutical and construction installation sectors.
முக்கிய அம்சங்கள்
Approved investment of up to ₹24 crore in UAE-based Fabtech Technologies LLC to achieve operational synergies.Approved ₹2.49 crore investment in FT Institutions Private Limited, a subsidiary focused on pharmaceutical and healthcare capabilities.FT Institutions Private Limited reported a significant turnover growth to ₹1,261.56 lakhs in FY26 from ₹697.06 lakhs in FY25.Fabtech Technologies LLC (UAE) reported nil turnover and a net loss of AED 1,19,226 for the year ended March 31, 2026.Reconstituted Audit, NRC, and CSR committees following the completion of tenure of Independent Director Shyam Nagorao Khante.
👀 கவனிக்க வேண்டியவை
Investors should view the capital infusion as a growth signal, particularly the scaling of the Indian subsidiary; however, they should monitor the UAE unit's ability to generate revenue following this investment.
Fabtech FY26 Revenue Up 25.7% to ₹411 Cr; Order Book Surpasses ₹900 Cr
Fabtech Technologies reported a strong FY26 with revenue growing 25.7% YoY to ₹410.77 crore and an operational profit of ₹36.60 crore. The company maintains a robust order book of over ₹900 crore, providing significant revenue visibility for the coming years. Management is targeting a margin expansion from the current 8-9% to 11-13% through localisation in the UAE/KSA and expanding into Pre-Engineered Building (PEB) scopes. For FY27, the company has guided for a standalone revenue of ₹500 crore and a PAT of ₹45 crore.
முக்கிய அம்சங்கள்
Revenue from operations grew 25.7% YoY to ₹410.77 Cr in FY26Consolidated order book stands at ₹900+ Cr as of March 31, 2026, ensuring high revenue visibilitySecured major turnkey projects in Saudi Arabia (~₹65.5 Cr) and West Africa (~₹63.6 Cr)Management guidance for FY27 projects standalone revenue of ₹500 Cr and PAT of ₹45 CrStrategic roadmap to increase PAT margins to 11-13% via European acquisitions and PEB scope control
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹900 Cr order book and the impact of the European acquisition on margins. The company's shift to a domestic status in KSA and UAE is a key catalyst for long-term profitability.
Fabtech Technologies Secures ₹31.23 Crore Veterinary Vaccine Project in Botswana
Fabtech Technologies Limited has secured a ₹31.23 crore contract for a new Veterinary Vaccine Manufacturing Facility in Botswana. The project involves providing critical internal infrastructure, including GMP-compliant HVAC systems, clean utilities, and MEP services. This win strengthens the company's presence in the African healthcare and biotechnology sectors. It aligns with the regional push for vaccine self-sufficiency and highlights Fabtech's specialized capabilities in life sciences infrastructure.
முக்கிய அம்சங்கள்
Awarded a ₹31.23 crore contract for a veterinary vaccine facility in Botswana.Scope includes GMP-compliant internal infrastructure, precision HVAC, and MEP services.Strengthens the company's footprint in the growing African vaccine manufacturing market.Project supports regional goals of animal health, food security, and reduced import dependence.Reinforces Fabtech's position as a specialized Life Sciences Infrastructure Platform.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's international order book and specialized engineering segment. Monitor the execution timeline and potential for further high-margin contracts in the African biologics space.
Fabtech Technologies Promoters Declare Zero Share Encumbrance for FY 2025-26
Fabtech Technologies Limited has filed a disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The promoter, Aasif Ahsan Khan, acting on behalf of the entire promoter group, confirmed that no encumbrances were created on their shareholding during the financial year ended March 31, 2026. This declaration covers a total of 66 entities and individuals within the promoter and promoter group. Such disclosures are mandatory annual filings to ensure transparency regarding promoter share pledging.
முக்கிய அம்சங்கள்
Promoters and Promoter Group confirmed zero direct or indirect encumbrance on shares for FY 2025-26.The disclosure was submitted in compliance with Regulation 31(4) and 31(5) of SEBI (SAST) Regulations, 2011.A total of 66 promoter group entities and individuals are covered under this non-encumbrance declaration.The filing was formally submitted to both the National Stock Exchange (NSE) and BSE Limited on April 8, 2026.
👀 கவனிக்க வேண்டியவை
Investors should take this as a sign of financial stability and promoter confidence, as the absence of pledged shares reduces risk. No immediate action is required other than noting the clean shareholding status.
Fabtech Technologies to Form 51% Step-Down Subsidiary in Saudi Arabia for Expansion
Fabtech Technologies Limited, through its wholly owned subsidiary Fabtech Technologies LLC, has entered into a shareholders agreement to incorporate a new entity in Saudi Arabia. The new company, Specialized Contracting Activities LLC, will be a step-down subsidiary with Fabtech's subsidiary holding a 51% stake. This venture marks a strategic entry into the Saudi Arabian market, focusing on specialized mechanical, electrical, plumbing, and civil contracting for non-pharmaceutical industries. The investment will be a 100% cash subscription at face value.
முக்கிய அம்சங்கள்
Fabtech's subsidiary to hold a controlling 51% stake in the new Saudi Arabian entity.The new company will focus on MEP and Civil contracting for non-pharma industries in KSA.Partnership formed with Mr. Saleh Mousa Eidhah Al-Zahrani and Specialized Contracting Activities LLC.Investment is structured as a 100% cash consideration at face value per share.The move signifies geographical and sectoral diversification for Fabtech Technologies.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth move into the high-potential Saudi market; monitor for future project announcements and the impact on consolidated margins.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
